{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:13:13Z","timestamp":1789668793750,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.semarthrit.2026.152976","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:04:52Z","timestamp":1775840692000},"page":"152976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical relevance of specific and non-specific autoantibodies in systemic sclerosis without overlap features"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6526-0140","authenticated-orcid":false,"given":"Andre S.","family":"Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0533-8353","authenticated-orcid":false,"given":"Mateus Cavarzan","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7168-5906","authenticated-orcid":false,"given":"Ana Cristina","family":"Medeiros-Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0516-6918","authenticated-orcid":false,"given":"Ana Paula","family":"Luppino-Assad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6194-5129","authenticated-orcid":false,"given":"Eduardo F.","family":"Borba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-601X","authenticated-orcid":false,"given":"Renata","family":"Miossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9457-3317","authenticated-orcid":false,"given":"Elaine P.","family":"Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7343-6804","authenticated-orcid":false,"given":"Sandra G.","family":"Pasoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-4681","authenticated-orcid":false,"given":"Elo\u00edsa","family":"Bonfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9843-6686","authenticated-orcid":false,"given":"Percival D.","family":"Sampaio-Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2026.152976_bib0001","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0002","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0003","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0004","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","article-title":"Antinuclear antibodies in systemic sclerosis: an update","volume":"58","author":"Stochmal","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0005","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0006","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/annrheumdis-2013-204487","article-title":"Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis","volume":"74","author":"Moinzadeh","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0007","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0008","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European league against rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0009","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American college of rheumatology\/European league against rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0011","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1007\/s10067-022-06286-w","article-title":"The enigma of mixed connective tissue disease-challenges in routine care","volume":"41","author":"Wanzenried","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0012","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0013","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.1016\/S2665-9913(22)00217-X","article-title":"Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort","volume":"4","author":"Elhai","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0014","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/BOR.0000000000001035","article-title":"Autoantibodies as putative biomarkers and triggers of cell dysfunctions in systemic sclerosis","volume":"37","author":"Rosa","year":"2025","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0015","doi-asserted-by":"crossref","DOI":"10.1177\/23971983251324827","article-title":"Interstitial lung disease in anti-U1RNP systemic sclerosis patients: a European Scleroderma trials and research analysis","author":"Boleto","year":"2025","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103220","article-title":"Anti-U1RNP antibodies are associated with a distinct clinical phenotype and a worse survival in patients with systemic sclerosis","volume":"146","author":"Chevalier","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0017","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/RHU.0000000000001127","article-title":"Characterization of interstitial lung disease associated with anti-ribonucleoprotein antibodies","volume":"26","author":"Lhote","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152861","article-title":"Circulating biomarkers and detection of pulmonary diseases in patients with systemic lupus erythematosus: a systematic review and meta-analysis of observational studies","volume":"75","author":"Langkilde","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0019","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.3899\/jrheum.101248","article-title":"Clinical and serological hallmarks of systemic sclerosis overlap syndromes","volume":"38","author":"Pakozdi","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15062-4","article-title":"Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes","volume":"12","author":"Clark","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0021","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/1756-185X.12884","article-title":"Clinical characteristics of scleroderma overlap syndromes: comparisons with pure scleroderma","volume":"19","author":"Foocharoen","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0022","first-page":"126","article-title":"Autoantibody profile in a cohort of Algerian patients with systemic sclerosis","volume":"78","author":"Tahiat","year":"2020","journal-title":"Ann Biol Clin"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0023","doi-asserted-by":"crossref","DOI":"10.1186\/ar3495","article-title":"Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features","volume":"13","author":"Mierau","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0024","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.autrev.2006.08.007","article-title":"Anti-RNP immunity: implications for tissue injury and the pathogenesis of connective tissue disease","volume":"6","author":"Keith","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0025","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1002\/art.39316","article-title":"Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (scleroderma) cohort using principal components analysis","volume":"67","author":"Patterson","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0026","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/03009742.2021.1887927","article-title":"Anti-Ro52\/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients","volume":"50","author":"Lee","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0027","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12016-022-08946-w","article-title":"Systemic sclerosis-specific antibodies: novel and classical biomarkers","volume":"64","author":"Cavazzana","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0028","doi-asserted-by":"crossref","DOI":"10.1186\/ar3763","article-title":"Clinical significance of antibodies to Ro52\/TRIM21 in systemic sclerosis","volume":"14","author":"Hudson","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"4 Suppl 91","key":"10.1016\/j.semarthrit.2026.152976_bib0029","article-title":"Monospecific anti-Ro52\/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival","volume":"33","author":"Wodkowski","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0030","article-title":"Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis","volume":"10","author":"Nayebirad","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.103013","article-title":"An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management","volume":"21","author":"Decker","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102943","article-title":"Systematic review of anti-dsDNA testing for systemic lupus erythematosus: a meta-analysis of the diagnostic test specificity of an anti-dsDNA fluorescence enzyme immunoassay","volume":"20","author":"Orme","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0033","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12026-022-09347-z","article-title":"ANA-specific antibodies, ANA patterns, anti-ds-DNA results, and clinical diagnosis: a laboratory and clinical audit","volume":"71","author":"Anis","year":"2023","journal-title":"Immunol Res"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.152976_bib0034","first-page":"693","article-title":"Characteristics of Overlap Syndrome in a Large Cohort of Brazilian Patients With Systemic Sclerosis: A Retrospective Analysis","volume":"52","author":"Gama","year":"2025","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0035","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3109\/08916934.2011.592886","article-title":"Distinctive autoantibody profile in Mexican Mestizo systemic sclerosis patients","volume":"44","author":"Rodriguez-Reyna","year":"2011","journal-title":"Autoimmunity"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2020.06.021","article-title":"Extended myositis-specific and -associated antibodies profile in systemic sclerosis: a cross-sectional study","volume":"88","author":"Leurs","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0037","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s10067-014-2730-z","article-title":"Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis","volume":"33","author":"Aguila","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0038","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/art.1780390218","article-title":"Sensitivity and specificity of anti-Jo-1 antibodies in autoimmune diseases with myositis","volume":"39","author":"V\u00e1zquez-Abad","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0039","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.3389\/fimmu.2018.02457","article-title":"Prevalence and clinical associations of antiphospholipid antibodies in systemic sclerosis: new data from a French cross-sectional study, systematic review, and meta-analysis","volume":"9","author":"Sobanski","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0040","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.semarthrit.2016.10.004","article-title":"Clinical relevance of antiphospholipid antibodies in systemic sclerosis: a systematic review and meta-analysis","volume":"46","author":"Merashli","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0041","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001012","article-title":"Association of antiphospholipid antibodies with active digital ulceration in systemic sclerosis","volume":"5","author":"Martin","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0042","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/rheumatology\/keq205","article-title":"Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis","volume":"49","author":"Ueda-Hayakawa","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0043","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/1756-185X.13330","article-title":"Significance of combined anti-CCP antibodies and rheumatoid factor in a New Zealand cohort of patients with systemic sclerosis","volume":"21","author":"Kamalaksha","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0044","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.17219\/acem\/69921","article-title":"Anti-CCP antibodies and rheumatoid factor in systemic sclerosis: prevalence and relationships with joint manifestations","volume":"27","author":"Wielosz","year":"2018","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0045","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jbspin.2017.11.006","article-title":"Anti-citrullinated peptides antibodies in systemic sclerosis: meta-analysis of frequency and meaning","volume":"85","author":"Laustriat","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2026.152976_bib0046","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23180-2","article-title":"A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and interstitial lung disease in systemic sclerosis","volume":"12","author":"Ha","year":"2022","journal-title":"Sci Rep"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722600065X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722600065X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:57:45Z","timestamp":1789667865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004901722600065X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":46,"alternative-id":["S004901722600065X"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152976","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical relevance of specific and non-specific autoantibodies in systemic sclerosis without overlap features","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152976","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152976"}}